Back to Search
Start Over
Sustained hair regrowth with continued ritlecitinib treatment through Week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b/3 trial.
- Source :
-
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Oct 16. Date of Electronic Publication: 2024 Oct 16. - Publication Year :
- 2024
- Publisher :
- Ahead of Print
-
Abstract
- Background: Few treatments for alopecia areata (AA) have demonstrated sustained efficacy.<br />Objective: Evaluate the efficacy and safety of continued ritlecitinib treatment to Week 48 in patients with AA with or without target efficacy responses at Week 24.<br />Methods: Patients aged ≥12 years received daily ritlecitinib (± 4-week loading dose): 200/50 mg, 200/30 mg, 50 mg, or 30 mg. Patients with clinical response at Week 24, based on a Severity of Alopecia Tool (SALT) score ≤20 and ≤10 were evaluated for sustained response through Week 48. Nonresponders at Week 24 were assessed for response through Week 48.<br />Results: Among ritlecitinib-treated patients with SALT score ≤20 and ≤10 responses at Week 24, ≥85% and ≥68%, respectively, sustained these responses through Week 48. Of those with SALT score >20 at Week 24, 22%-34% achieved SALT score ≤20 at Week 48. Of those with a SALT score >10 at Week 24, 20%-26% achieved SALT score ≤10 at Week 48. Safety was similar across subgroups.<br />Limitations: Small sample size.<br />Conclusion: Hair regrowth was sustained through Week 48 in patients with response at Week 24. Up to one-third of patients who did not meet target efficacy at Week 24 achieved response with continued ritlecitinib treatment.<br /> (Copyright © 2024. Published by Elsevier Inc.)
Details
- Language :
- English
- ISSN :
- 1097-6787
- Database :
- MEDLINE
- Journal :
- Journal of the American Academy of Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 39423930
- Full Text :
- https://doi.org/10.1016/j.jaad.2024.09.064